The Interreg project Codex4SMEs (Companion diagnostics expedited for small and medium-sized businesses) project plans to improve healthcare by enhanced adoption of Personalized Medicine in North-West Europe. The objective is to establish a network, which supports SMEs along the value chain of Companion diagnostics (Cdx) development.
Companion diagnostics (Cdx) are an indispensable tool for optimum application of Personalized Medicine: they allow tests to determine the molecular causes of a disease before treatment has started. However, thus far the development of companion diagnostics has been highly time-consuming and costly, so at present it is only used in the context of very few treatments.
Codex4SMEs will establish a transnational network of nine partners and two sub-partners from seven countries and expedite the development of the SMEs’ products in the field of Cdx. There is a need to improve SMEs‘ innovative capabilities and raise both international competitiveness and the impact of North-West Europe SMEs in this global market as the USA are far ahead - Codex4SMEs will directly address this challenge.
Benefits for SMEs
Posted on 02-10-2020
The Biomarker Commercialisation Support Tool was succesfully launched on September 22nd. Please find here a recording of the webinar with the introduction to the tool. Read more
Posted on 13-05-2020
On May 11th, 2020, the Codex4SMEs-project organized an online event highlighting "Digital Health Data in Personalized Medicine". Please find the audio of the event and the slides o... Read more
1 University Road
Leicester
LE1 7RH
United Kingdom
15 Goirlese Weg
Tilburg
5026
Netherlands
Galway Technology Centre Mervue Business Park
Galway
H91 E2W5
Ireland
32 Prinses Margrietplantsoen
Den Haag
2595
Netherlands
3-5 Impasse Reille
Paris
75014
France
6 Rue Nicolas Ernest Barblé
Luxembourg
L-1210
Luxembourg
2 Auenbruggerplatz
Graz
A-8036
Austria
Biomedical Sciences National University of Ireland Galway
Galway
H91 TK33
Ireland
10 Friedrichstrasse
Stuttgart
70174
Germany
Lead partner
| Organisation | Address | Website | |
|---|---|---|---|
| BioRegio STERN Managment GmbH, DE |
10 Friedrichstrasse Stuttgart 70174 Germany |
jehle@bioregio-stern.de | www.bioregio-stern.de |
| Name | Contact Name | Country | |
|---|---|---|---|
| University of Leicester, UK | Carl M Edwards | ce133@le.ac.uk | United Kingdom |
| BOM Holding BV, NL | Maria Hein | rhein@bom.nl | Netherlands |
| Innovation and Management Centre Limited T/A WestBIC, IE | Eunan Cunningham | ecunningham@westbic.ie | Ireland |
| InnovationQuarter, NL | Lonneke Baas | Lonneke.baas@innovationquarter.nl | Netherlands |
| Medicen Paris Region, FR | Daniela Onofri | donofri@medicen.org | France |
| Integrated BioBank of Luxembourg, LU | Monica Marchese | Codex4SMEs@ibbl.lu | Luxembourg |
| Biobank Graz @ Medizinische Universität Graz, AT | Sarah Frajuk | codex4smes@medunigraz.at | Austria |
| CÚRAM Centre for Research in Medical Devices, IE | John Cunningham | jcunningham@nuigalway.ie | Ireland |
Join over 450 leaders, experts and scientists at the renowned Biomarkers Series, discussing key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials
Read More
‘Diagnostics-4-Future Conference‘ is the international meeting-place for users and providers from industry and science.
Based on questions in medical care, clinics and laboratories, innovative solutions for new diagnostics are discussed including research and development. The focus is also on solutions for rural areas (point-of-care). Organizer is the international health network BioLAGO. The conference emerged from the DiagNET project.
Read More
To meet the challenges in healthcare of the 21st century, we need to develop novel approaches by combining Bioengineering and Medtech to cancer diagnosis and prognosis. Each has a role to play in this open innovation model: clinician, engineers, industrials, entrepreneurs, doctors, MedTech companies and, of course, patients.
Read More
Europe Biobank Week 2020 will take place between 17-20 November in a virtual format for the first time. The largest biobanking conference in Europe will be fully digitized this year! The conference is a joint effort of ESBB and BBMRI-ERIC. Last year’s edition in Lübeck saw the largest number of abstracts submitted (over 280) and over 750 professionals came together to discuss, network, engage, and promote knowledge around biobanking.
Read More
Inside the Biobank of Graz - get to know one of the biggest biobanks in the world and find out more about the sample collection they have!
Read More
The Interreg NWE project Codex4SMEs is proud to organise this interactive online seminar with Hans Peter Mulder addressing the topic: If liquid biopsies are 100% efficient, they would still yield only a handful of cancer cells per blood sample. How reliable can a diagnostic test be when you're limited to a handful of cancer cells?
Read More
The MarketsandMarkets Biomarker & CDx week is here!
After organizing 14 successful events in past 4 month we are coming up with our flagship event, MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference from 20th - 23rd October 2020 (Time Zone: Eastern Standard Time EST)
Read More
VISIONARY SEMINAR, INTERNATIONAL MATCHMAKING and CRASH COURSE FOR ENTREPRENEURS
Set of 3 events on 7., 8. and 14.Oct 2020.
Read More
The Biomarker Commercialisation Support Tool was succesfully launched on September 22nd. Please find here a recording of the webinar with the introduction to the tool. Read More
On May 11th, 2020, the Codex4SMEs-project organized an online event highlighting "Digital Health Data in Personalized Medicine". Please find the audio of the event and the slides of the speakers' presentations under this 'News'-item. Read More
A healthy future with good and affordable healthcare demands smart solutions. But those types of solutions don´t just appear out of thin air. To realise this, you need people with ground breaking ideas, energy, perseverance and a relentless belief in the added value represented by collaborations. You could find these kind of people at the Innovation for health congress in Rotterdam. On February 13th in the framework of the congress, the Codex4SMEs break-out session took place. Read More
Codex4SMEs gave SMEs the opportunity to pitch their project in front of investors in Palais Brongniart, Paris, in partnership with EIT Health Summit 2019. Read More
Our associated partner EATRIS (European Infrastructure for Translational Medicine) is offering support via their new developed virtual learning platform 'TRANSMED academy': To support biomedical researchers to gain better understanding of translational research and medicines development, EATRIS has developed a learning platform, offering access to several online activities, free of charge. Online training modules are a great way to provide high quality, accessible, interactive training at all levels. Read More
At the 18th September 2019, the 4th Double Session took part in Galway. A double session includes both, informative talks about the topics of regulation and market of IVD companies and a dedicated time frame to meet other key players, stakeholders or potential new collaboration partners. Read More
WestBIC, CÚRAM, the Science Foundation Ireland Research Centre for Medical Devices at NUI Galway, and their European partners in Codex4SMEs Information and Networking Event are to host the Interreg North-West Europe project Codex4SMEs (Companion Diagnostics Expedited for Small and Medium-sized Enterprises) on Wednesday, 18 September, at Hotel Meyrick, Galway. Read More
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME. A total of four award winners will receive a grant of approximately 100,000 Euros each, in the form of laboratory services by the Integrated Biobank of Luxembourg. Read More
Four companies from Germany, France and the Netherlands have been presented with the Biomarker Validation Award as part of Codex4SMEs. The European project aims to establish a transnational network to accelerate the development of companion diagnostics along the entire value chain of small and medium-sized enterprises. The award is endowed with approximately EUR 100,000, which is handed over in the form of laboratory services. The chosen companies can now have their respective biomarkers validated by the Integrated Biobank of Luxembourg – in other words, have them tested to assess their reliability with regard to their relevant indication. Read More
The Interreg project Codex4SMEs (Companion diagnostics expedited for small and medium-sized businesses) project plans to improve healthcare by enhanced adoption of Personalized Medicine in North-West Europe. The objective is to establish a network, which supports SMEs along the value chain of Companion diagnostics (Cdx) development. Read More
Services provided by the biobank project partners will be covered 100 % of the costs by the project.
Following services are still available within the project:
Look into specific collections & cohorts here
Samples for pilot projects
- to test or establish a new method
- clinical samples from a maximum number of 5 patients
- no ethics vote required
- Results must not be published
Samples for research projects
- sample access for research projects/biomarker research
- clinical samples from a maximum number of 20 patients
- valid ethics vote mandatory
Sample Access and Knowledge Transfer services will be available continously.
Please note: there is a limited number of services available and will be revised following a 'fist come first serve basis'.
For interested SMEs the guidelines and the application documents are available for download below.
Do not hesitate to get in contact with your local Codex4SMEs-partner and/or the Biobank of Graz directly (codex4smes@medunigraz.at).
Earlier in the project, the Integrated Biobank of Luxembourg (IBBL) offered a Biomarker validation serivce for the Codex4SMEs-community. Five SMEs were awarded with the service during two call periods:
For evaluation of the application forms and professional recommendations to the Codex4SMEs-consortium, an independent expert group was integrated.
The members were:
The Codex4SMEs-consortium would like to thank the expert group for their support, their time for revising the applications and helping us selecting the winners!
The Advisory Board acts as an observing body. They provide insights and recommendations on different topics in the framework of Cdx to support the project.
These are the members:
The map gives an overview of companies which are active in the field of companion diagnostics in the partner regions. When you klick at one selected company, further information like the main activities or the contact datails are mentioned.
Be part of the Codex4SMEs network, contact your regional partner and get an entry on the map.
Benefit from the Codex4SMEs projekt and get tailored support depending on your product TRL level. Furthermore you get access to:
Please note: costs for samples and/or other activities from other than the Biobank of Graz cannot be covered by the project.
Fingenious is a
Feasibility and access costs (FINBB)
Please find their homepage here.
Your contact person is Marieke Huis in 't Veld: mhuisintveld@bom.nl
One critical hurdle for developers of (companion) diagnostics is obtaining the right information on regulatory and reimbursement issues. In order to facilitate the access to such information, the Codex4SMEs project provides SMEs from the field of (companion) diagnostics a list of information that compiles all relevant links on this topic.
| Institution | Description | Type |
| Foundation for the National Institutes of Health (FNIH) | The Biomarkers Consortium | Biomarker R&D |
| Health and environmental sciences institute (HESI) | Health and environmental sciences institute | Healthcare R&D |
| ISPOR | France Medical Device - Global Health Technology Assessment Road Map | Reimbursement and Regulatory |
| Personalized Medicine Coalition (PMC) | Personalized Medicine in the Clinic | Advocacy Group |
| Personalized Medicine Coalition (PMC) | Advancing Access to Personalized Medicine: A Comparative Assessment of European Reimbursement Systems | Advocacy Group |
| Personalized Medicine Coalition (PMC) | Personalized Medicine at FDA: an annual research report | Advocacy Group |
| Personalized Medicine Coalition (PMC) | Personalized Medicine Coalition | Advocacy Group |
| Institution | Description | Type |
| European Molecular Quality Network (EMQN) | Not-for-profit community interest company (CIC) promoting quality in genetic testing by establishing, harmonising and disseminating best practice | Best Practice |
| MTR Consulting | Innovative payment schemes for medical technologies and in vitro diagnostic tests in Europe | Reimbursement |
| MTR Consulting | Challenges of the European market access function in a medical device company | Market Access |
| MTR Consulting | Key trends in European market access for medical technologies | Market Access |
| Institution | Description | Type |
| Competent Authorities for Medical Devices (CAMD) | CAMD Implementation Taskforce: Medical Devices Regulation/In-vitro Diagnostics Regulation (MDR/IVDR) Roadmap | Regulatory |
| EuroGentest | Harmonisation of genetic testing across Europe |
Regulatory |
| European database on medical devices (EUDAMED) | registration system, a collaborative system, a notification system, a dissemination system | Regulatory |
| European In vitro diagnostic Regulation (IVDR) | EGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 | Regulatory |
| European Medical Agency (EMC) | Scientific evaluation, supervision and safety monitoring of medicines in the EU | Regulatory |
| European Medical Device Regulation (MDR) | REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 | Regulatory |
| European Society of Human Genetics (ESHG) | ESHG promotes research in basic and applied human and medical genetics | Healthcare R&D |
| List of Notified Bodies | Notified bodies responsible for the certification of IVD according to Regulation (EU) 2017/746 on in vitro diagnostic medical devices | Regulatory |
| Overview of European regulatory framework for medical devices and in vitro diagnostic medical devices. | Regulatory |
| Institution | Description | Type |
| Alliance Aviesan et à ses membres, né des investissements d’Avenir (AVIESAN) | BMK Tools for biomarker developers | Biomarker R&D |
| Alliance nationale pour les sciences de la vie et de la santé (AVIESAN) | French National Alliance for Life Sciences and Health: Coordination of national research policies | Biomarker R&D |
| Haute Autorité de Santé (HAS) | Recommendations that aid public authorities in reimbursement and pricing decision-making with regards to the French national health fund | Reimbursement |
| Institut National du Cancer (INCA) | French National Cancer Institute: health and science agency in charge of cancer control in France | Regulatory |
| Agence nationale de sécurité du médicament et des produits de santé (ANSM) | National Agency for Medicines and Health Products Safety (France) | Regulatory |
| Institution | Description | Type |
| Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) | General information on the regulation of deployment of medical apps in Germany: Digitale-Versorgung-Gesetz | Regulatory |
| Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) | Legal text of Digitale-Versorgung-Gesetz–DVG (Regulation of medical apps in Germany) | Regulatory |
| DEKRA | Notified Body responsible for IVD certification | Regulatory |
| German Institute of Medical Documentation and Information (DIMDI) | Notifications Medical Devices and In vitro Diagnostics | Regulatory |
| Gemeinsame Bundesausschuss The federal joint Committee (G-BA) | The federal joint Committee (G-BA): Reimbursement of Medical Devices and Drugs in Germany | Reimbursement |
| Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). |
Institute for Quality and Efficiency in Health Care (IQWiG): IQWiG examines the advantages and disadvantages of medicine services - in certain cases also theirs costs, | Reimbursement and Regulatory |
| Institution | Description | Type |
| Health Products Regulatory Authority (HPRA) | Guide for Manufacturers of General Class In-Vitro Diagnostic Medical Devices | Regulatory |
| Health Products Regulatory Authority (HPRA) | New EU Device Legislation Information Pack | Regulatory |
| Health Products Regulatory Authority (HPRA) | Key aspects specific to the in-vitro Diagnostics Regulation (IVDR) | Regulatory |
| Institution | Description | Type |
| Health and Youth Care Inspectorate | Registration and deregistration of medical devices or IVD's | Regulatory |
| Institution | Description | Type |
| Medicines and Healthcare products Regulatory Agency (MHRA) | In vitro diagnostic medical devices: guidance on legislation | Regulatory |
| Medicines and Healthcare products Regulatory Agency (MHRA) | Medical devices: how to comply with the legal requirements. Placement of a medical device in the UK market. | Regulatory |
Your contact person:
Aalborg University Hospital
Valérie Daussin Laurent
+4597666 297
Planning to commercialize your biomarker invention?
Thousands of candidate biomarkers are being discovered and the number of publications has exploded in recent years, but the discovery of a candidate biomarker is just the beginning of a long road to a commercial product.
Few findings enter to the specific assay development phase, pass the evaluation of analytical and clinical performance characteristics, and are eventually transformed into IVD assays, as biomarker development and commercialization is complicated, time consuming and expensive.
To support and help the commercialization process of new in vitro diagnostics (IVD)-applicable biomarkers, a set of tools and useful information was made available free of charge. The tools give structure and validation to biomarker research. They guide researchers and product developers through the technology readiness levels and remind about the clinical, regulatory, and business aspects of the innovation process.
The tools are only intended as guidance. They have been compiled to the best of our knowledge from a wide variety of sources, but cannot claim to be complete. Each new discovery or development is individual, therefore all information and mentioned standards have to be considered for the concrete individual case. As soon as possible, think of establishing a dialogue with specialists and experts in the field.
The tools are intended for researchers, SMEs and technology transfer offices and are available to all free of charge.
Choose a tool to get started:
The BIC Guide supports academic researchers and SMEs when developing an in-vitro diagnostic biomarker invention to a commercial product. It provides guidance through the technology readiness levels (TRL) and covers the clinical, regulatory, and business aspects of the commercialization process. The tasks are described and partially supported by useful, downloadable documents. The guide supports the potential commercialization and guides you through dialogue with industrial partners.
an Interreg North-West-Europe - project
Your contact person:
Noord-Brabant Development Agency (BOM)
Ria Hein
+31 6 52 607 187
Connect to your clients in North-West Europe!
Looking for new contacts and clients in North-West Europe? Make sure that you are in the online database of Boost4Health!
Within Boost4Health we aim to connect SMEs and service providers, to help SMEs making the next step. SMEs out of the Boost4Health regions have access to vouchers. Vouchers to spend in North-West Europe, maybe at your organisation! Make sure you are visible now for those SMEs! They are looking for service providers in the field of Lifesciences and Medical Devices. The vouchers can be used for specific expertises in the field of e.g. market insight. Make use of this business opportunity and connect through Boost4Health and the database.
